Day: July 3, 2022

Reference is made to the stock exchange announcement by Hofseth BioCare ASA (the “Company“) on 3 July 2022 regarding completion of a private placement of new shares (the “Private Placement“). In the Private Placement, the Company will issue a total of 35,490,000 new shares. Aqua-Spark Coöperatieve U.A. applied for and was allocated 10,350,000 shares in the Private Placement at a price per share of NOK 4.  After the issuance of the new shares in the Private Placement, the shareholding of Aqua-Spark will be more than 5% of the Company’s share capital. Following the Private Placement, Aqua-Spark will hold 22,450,000 shares in the Company, corresponding to 5.71% of the shares and votes outstanding after completion of the Private Placement. This information is subject to the disclosure requirements pursuant to...

Reference is made to the stock exchange notice from Hofseth BioCare ASA (“HBC” or the “Company”) published on 3 July 2022 regarding the completion of a private placement raising gross proceeds of approximately NOK 141 million (the “Private Placement”) through issuance of new shares (the “Offer Shares”) in the Company with a subscription price of NOK 4 per Offer Share (the “Offer Price”). The following persons discharging managerial responsibilities and their close associates have been allocated Offer Shares the Private Placement at the Offer Price: i) RH Industri AS, a close associate of CEO Roger Hofseth, has been allocated 17,800,190 Offer Shares, for a total subscription amount of NOK 71,200,760; andii) In order to facilitate for partial settlement on a delivery versus payment...

Four leading experts in respiratory allergy spotlight the impact of respiratory allergy in children, in an ALK-sponsored symposium at the EAACI Congress The growing availability of evidence-based allergy immunotherapy treatments for paediatric patients offers increased treatment options for prescribers ALK has enrolled more than 3,000 paediatric patients in eight Phase III clinical trials of its SLIT-tablets, as it pursues indications for children and adolescents around the worldALK has thrown a spotlight onto paediatric respiratory allergy and the major treatment advances seen in recent years at a company-sponsored symposium at the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI), in Prague, Czechia this week. In a session presented by four of the world’s leading experts in respiratory allergy, EAACI...